Investors and Media
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
March 13, 2023 at 1:20 PM EDT
February 23, 2023 at 1:00 PM EST
February 16, 2023 at 10:00 AM EST
March 16, 2023
January 17, 2023
December 8, 2022